# US 8,277,843 B2 · Programmable buoyant delivery technology

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,843 B2
- Document ID: US8277843B2
- Status: Granted
- Kind: B2
- Application number: 12/439,775
- Filed: 2007-09-03
- Published: 2010-01-21
- Granted: 2012-10-02
- Earliest claimed: 2006-09-04
- Assignees: Panacea Biotec Limited
- Inventors: Amarjit Singh; Sarabjit Singh; Shivanand Puthli; Rajendra Tandale
- Web page: https://patentgrep.com/patent/US8277843B2

## CPC

- A61K 9/0065: {Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus}
- A61P 1/06: Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K 9/2072: {characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms (A61K9/0004, A61K9/0056, A61K9/0065 take precedence)}
- A61K 9/2086: {Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat (active cores with a complete drug-free outer coat A61K9/28)}
- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K 9/2095: {Tabletting processes}
- A61K 9/2886: {having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer (of the type active core-drug layer-inactive layer A61K9/209)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is concerned with a system for spatially and temporally programmable delivery of an active agent. When administered orally, the System can be retained in the gastric region for a prolonged period of time. It comprises of a core (I), one or more layers (II, IV, V) coated over the core and a preformed hollow space (III). The invention also concerns with a process for preparation of the System and a method for treating/preventing diseases, by administering to a subject in need thereof, the System of the invention.

## Claims

### Claim 1

A buoyant system for spatially and temporally programmable delivery of an active agent comprising a solid core, one or more layers coated over the core and a preformed hollow space; wherein the active agent is present in the core or any of the layers of the system and wherein the preformed hollow space is present between two or more layers or between the core and one or more layers of the system or both.

### Claim 2 (depends on 1)

The system of claim 1 comprising a core, a polymeric layer, an active agent containing layer coated over the polymeric layer and a preformed hollow space.

### Claim 3 (depends on 2)

The system of claim 2 comprising an additional polymeric layer coated over the core.

### Claim 4 (depends on 2)

The system of claim 2 wherein an active agent is also present in the core and wherein the active agent is same or different from that present in the active agent containing layer.

### Claim 5 (depends on 2)

The system of claim 2 comprising
a core optionally comprising an active agent;
a first polymeric layer comprising a hydrophilic material;
a second polymeric layer comprising a polymer substantially insoluble in the gastric fluid;
an active agent containing layer coated over the second polymeric layer;
and a preformed hollow space substantially present between the first polymeric layer and the second polymeric layer.

### Claim 6 (depends on 5)

The system of claim 5 further comprising an additional layer coated on the active agent containing layer, the core or the second polymeric layer, wherein the additional layer comprises of a hydrophilic material.

### Claim 7 (depends on 5)

The system of claim 5 wherein the core comprises of about 10% to about 99.5% w/w diluent, about 0% to about 50% w/w binder and about 0.05% to about 10% w/w of lubricant.

### Claim 8 (depends on 5)

The system of claim 5 wherein the core comprises of an active agent and an absorption enhancer, wherein the absorption enhancer is selected from the group of cell envelope disordering compounds, solvents, steroidal detergents, chelators; surfactants; bile salts; fatty; non-surfactants and combinations thereof.

### Claim 9 (depends on 5)

The system of claim 5 wherein the hydrophilic material of the first polymeric layer is selected from the group of celluloses, alkylcelluloses, alkali metal salts of carboxyalkylcelluloses, polysaccharides, polyacrylic acids and their salts, polymethacrylic acids and their salts, methacrylate copolymers, vinyl polymers and copolymers, polymers and copolymers of polyalkylene oxides and hygroscopic or deliquescent materials.

### Claim 10 (depends on 5)

The system of claim 5 wherein the polymer of the second polymeric layer is selected from the group of enteric cellulose derivatives, enteric acrylic acid-based polymers and copolymers, enteric maleic acid-based polymers and copolymers, enteric polyvinyl derivatives, zein, shellac, cellulose esters, ethylcellulose, cellulose acetate, and enzymatically degradable polymers.

### Claim 11 (depends on 5)

The system of claim 5 wherein the polymer of the second polymeric layer is selected from the group of acrylic and methacrylic acid based polymers and copolymers, ethylcellulose, cellulose acetate, hydroxypropyl methyl cellulose phthalate and cellulose acetate phthalate.

### Claim 12 (depends on 5)

The system of claim 5 wherein the second polymeric layer comprises of a plasticizer upto about 50% w/w of the dry weight of the polymer.

### Claim 13 (depends on 5)

The system of claim 5 wherein the second polymeric layer comprises of about 10% to about 100% w/w polymer, about 0% to about 40% w/w plasticizer and about 0% to about 50% w/w anti-tacking agent and wherein the polymer is coated in the range from about 5% to about 50% w/w of the system.

### Claim 14 (depends on 5)

The system of claim 5 wherein the active agent containing layer also comprises a matrix or coating of a rate controlling material selected from the group of natural and synthetic polymers, gums of plant, animal, mineral or synthetic origin, substituted or unsubstituted hydrocarbons, fatty acids, fatty alcohols, glyceryl esters of fatty acids, minerals, vegetable oils and waxes.

### Claim 15 (depends on 14)

The system of claim 14, wherein the rate controlling material is selected from the group of hydroxypropyl methyl cellulose, polyvinyl pyrrolidone, ethyl cellulose, and poly (methacrylate) co-polymers.

### Claim 16 (depends on 5)

The system of claim 5 wherein the active agent containing layer comprises of a mucoadhesive substance.

### Claim 17 (depends on 1)

The system of claim 1 wherein the active agent is selected from the group of active agents used for alzheimer's disease, antibiotics, antiulcers, anti-muscarinic agents, antivirals, anaesthetics, acromegaly agents, steroidal and non-steroidal anti-inflammatory agents, analgesics, antiasthmatics, anticancer agents, anticoagulants and antithrombotic agents, anticonvulsants, antidiabetics, antiemetics, alcohol abuse preparations, antiglaucoma, antiallergics, antihistamines, anti-infective agents, antiparkinsons, antiplatelet agents, antirheumatic agents, anti spasmodics and anticholinergic agents, antitussives, carbonic anhydrase inhibitors, cardiovascular agents, cholinesterase inhibitors, treatment of CNS disorders, CNS stimulants, contraceptives, cystic fibrosis management, dopamine receptor agonists, endometriosis management, erectile dysfunction therapy, urinary tract disinfectants, fertility agents, gastrointestinal agents, immunomodulators and immunosuppressives, vitamins, nutritives, memory enhancers, migraine preparations, muscle relaxants, nucleoside analogues, osteoporosis management, active agents for respiratory organs, parasympathomimetics, prostaglandins, P-gp inhibitors, psychotherapeutic agents, sedatives, hypnotics and tranquillizers, agents used for early morning pathologies, macromolecules and combinations thereof.

### Claim 18 (depends on 1)

The system of claim 1 wherein the active agent is selected from the group of nimesulide, carvedilol, fenofibrate, tacrolimus, baclofen, metformin, loratidine, pseudoephedrine sulfate, bicalutamide, tramadol and leuprolide enalapril, captopril, benazepril, lisinopril, ranitidine, famotidine, diltiazem, propranolol, verapamil, nifedipine, acyclovir, ciprofloxacin, simvastatin, atorvastatin, dasatinib, pravastatin, lovastatin, selegiline, midazolam, glimepiride, glipizide and nefazodone.

### Claim 19 (depends on 1)

The system of claim 1, wherein the active agent is selected from the class of active agents having enhanced solubility in the gastric pH.

### Claim 20 (depends on 1)

The system of claim 1, wherein the system is an immediate release or a modified release system and wherein the system is administered orally and is retained in the gastric region for a period of time from about 1 hour to about 18 hours.

### Claim 21 (depends on 4)

The system of claim 4 wherein the active agent present in the active agent containing layer is delivered in the gastric and/or the upper intestinal region and the active agent present in the core is delivered in the lower intestinal and/or the colonic region, when the system is administered orally.

### Claim 22 (depends on 21)

The system of claim 21 wherein the system exhibits pulsatile release, one pulse released on administration and the other pulse is released after a predetermined delay and wherein one or both the pulses are modified release pulses.

### Claim 23 (depends on 1)

The system of claim 1 comprising a core, one or more polymeric layers coated over the core and a preformed hollow space, wherein the active agent is present in the core and wherein the active agent is delivered as an immediate or modified release in the lower intestinal and/or the colonic region when the system is administered orally.

### Claim 24 (depends on 1)

The system of claim 1 comprising a core comprising an active agent, one or more layers coated over the core and a preformed hollow space; wherein the core comprises of a rate controlling material in a matrix or coating form.

### Claim 25 (depends on 1)

The system of claim 1 comprising
a core comprising a hydrophilic material;
a polymeric layer comprising a polymer substantially insoluble in the gastric fluid;
an active agent containing layer;
and a preformed hollow space wherein the preformed hollow space is present substantially between the core and the polymeric layer.

### Claim 26 (depends on 1)

The system of claim 1, wherein the system is in the form of a tablet, capsule, bead or a pellet.

### Claim 27 (depends on 1)

The system of claim 1 in the form of a tablet, wherein the tablet is round, oval, capsule shaped, spherical, cylindrical, triangular, square, rectangular or polygonal in shape.

### Claim 28 (depends on 2)

The system of claim 2 comprising
a core optionally comprising an active agent;
a first polymeric layer comprising a hydrophobic material;
a second polymeric layer comprising a polymer substantially insoluble in the gastric fluid;
an active agent containing layer coated over the second polymeric layer;
and a preformed hollow space substantially present between the first polymeric layer and the second polymeric layer.

### Claim 29

A process for manufacturing a buoyant system for spatially and temporally programmable delivery of an active agent, the system comprising a core, one or more layers coated over the core and a preformed hollow space, the process comprising the steps of:
i. manufacturing a core or using a preformed core, optionally with an active agent;
ii. optionally coating the core with a hydrophilic material to form the first polymeric layer;
iii. further coating the system with a polymer substantially insoluble in the gastric fluid to form the second polymeric layer;
iv. supplying energy and/or vacuum over a period ranging from about a few seconds to about 5 hours, causing the expansion of the second polymeric layer and generation of a hollow space; and
v. optionally coating the system manufactured in step iv) with an active agent to form an active agent containing layer.

### Claim 30 (depends on 29)

The process of claim 29, comprising the steps of:
i. manufacturing a core in the form of a tablet, optionally with an active agent;
ii. coating the core with a hydrophilic material to form the first polymeric layer;
iii. coating the system manufactured in step ii) with a polymer substantially insoluble in the gastric fluid to form the second polymeric layer;
iv. supplying heat in the range of about 40° C. to about 150° C. after step iii), causing the expansion of the second polymeric layer and subsequent cooling leading to generation of a hollow space; and
v. coating the system manufactured in step iv) with an active agent to form an active agent containing layer.

### Claim 31 (depends on 29)

The process of claim 29, further comprising the step of coating an additional layer on the active agent containing layer, the core or over the second polymeric layer, wherein the additional layer comprises of a hydrophilic material.

### Claim 32 (depends on 29)

The process of claim 29, wherein the hollow space comprises air, vapor, a gas, a mixture of gases or a partial vacuum.

### Claim 33 (depends on 29)

The process of claim 29, wherein the active agent containing layer is coated as a solution or dispersion of an active agent and an excipient.

### Claim 34 (depends on 29)

The process of claim 29, wherein the active agent containing layer is manufactured by coating a layer of an active agent followed by coating a layer of a rate controlling material.

### Claim 35

A buoyant system retained in the gastric region for a prolonged period of time comprising a solid core, one or more layers coated over the core and a preformed hollow space; wherein the active agent is present in the core or any of the layers of the system and wherein the preformed hollow space is substantially present between two or more layers or between the core and one or more layers of the system or both.

### Claim 36

A process for manufacturing a buoyant system having a density lesser than gastric fluid comprising the step of formation of a hollow space within the system due to expansion of one or more of its compartments, the expansion being caused by generation of a positive or negative pressure within the system.

### Claim 37 (depends on 36)

The process of claim 36, wherein the positive pressure is vapor pressure generated due to supply of energy and wherein the negative pressure is generated due to a supply of vacuum.

### Claim 38 (depends on 36)

The process of claim 36, wherein the expansion is caused by a combined supply of energy and vacuum.

### Claim 39 (depends on 37)

The process of claim 37, wherein the energy is heat, which is supplied in the range of about 40° C. to about 150° C.

### Claim 40 (depends on 37)

The process of claim 37, wherein the energy is supplied over a period ranging from about a few seconds to about 5 hours.

### Claim 41 (depends on 36)

A system manufactured by the process of claim 36, wherein the system comprises of a core, one or more layers coated over the core and the preformed hollow space.

### Claim 42 (depends on 9)

The system of claim 9 wherein the hydrophilic material of the first polymeric layer is selected from the group of polyvinyl alcohol, polyvinylpyrrolidone, vinylpyrrolidone-vinyl acetate copolymer and hydroxyalkylcelluloses in the range of from about 10% to about 100% w/w of the layer.

### Claim 43 (depends on 5)

The system of claim 5 wherein the hydrophilic material is coated in the range from about 2% to about 50% w/w of the system.

### Claim 44 (depends on 1)

The system of claim 1, wherein the active agent is selected from the class of active agents preferentially absorbed through the proximal region of the gastrointestinal tract.

### Claim 45 (depends on 1)

The system of claim 1, wherein the active agent is selected from the class of active agents, which act locally in the proximal region of the gastrointestinal tract.

### Claim 46 (depends on 1)

The system of claim 1, wherein the active agent is selected from the class of active agents degraded due to intestinal pH and/or enzymes.

### Claim 47 (depends on 1)

The system of claim 1, wherein the active agent is present in an amount ranging from about 0.5% to about 85% w/w of the system.
